What medications provide a distal sodium‑channel block for cardiac anti‑arrhythmic therapy and neuropathic pain, and how should they be selected and dosed based on the presence or absence of structural heart disease?

Distal Sodium Channel Block: Medication Selection and Dosing

Cardiac Anti-Arrhythmic Therapy

Sodium channel blockers (Class I antiarrhythmics) should be avoided in patients with structural heart disease due to increased mortality risk, but can be used selectively in patients without structural heart disease for specific arrhythmias. 1

Critical Contraindication Based on Structural Heart Disease

• Patients WITH structural heart disease (ischemic heart disease, prior MI, ventricular dysfunction): Sodium channel blockers are contraindicated based on CAST trial data showing increased mortality (7.7% vs 3.0% with placebo) in post-MI patients treated with Class IC agents 2
• Patients WITHOUT structural heart disease: Class IC agents (flecainide, propafenone) are appropriate first-line options for supraventricular arrhythmias 2, 3

Specific Cardiac Indications and Agent Selection

For paroxysmal atrial fibrillation/flutter or PSVT in structurally normal hearts:

• Flecainide: 50-200 mg twice daily for prevention of PAF/PSVT; initiate in hospital for sustained VT 3
• Propafenone: 150-300 mg three times daily for PAF/PSVT prevention 2
• Both agents require concomitant AV nodal blocking drugs to prevent 1:1 atrial flutter conduction 2, 3

For specific channelopathies and refractory ventricular arrhythmias:

• Mexiletine: Oral dosing for congenital long QT syndrome 1
• Quinidine: For Brugada syndrome 1
• Lidocaine: IV administration for refractory VT/cardiac arrest, especially witnessed arrests 1
• Ranolazine: 1000 mg twice daily for ICD patients with medication-resistant VT/VF; provides late sodium channel current blockade with atrial selectivity 1

Mechanism Considerations

• Ranolazine demonstrates preferential inactivated-state sodium channel blockade with 10-fold greater potency for persistent sodium current (INa(P)) versus transient current (INa(T)), providing atrial selectivity 4, 5
• Use-dependent block occurs primarily through drug association with inactivated sodium channels accessed via open channels 6

---

Neuropathic Pain Management

For neuropathic pain, sodium channel blockers are recommended as second-line agents after gabapentinoids and SNRIs, with topical formulations preferred when feasible.

First-Line Agents (Non-Sodium Channel Blockers)

• Gabapentinoids: Pregabalin or gabapentin supported by high-quality evidence 1
• SNRIs: Duloxetine (two high-quality studies) or venlafaxine (one high-quality study) 1

Sodium Channel Blockers for Neuropathic Pain

Topical agents (preferred for localized pain):

• Lidocaine 5% patches: Maximum 3 patches for 12 hours per 24-hour period; minimal systemic absorption 1, 7
• Capsaicin 8% patch: FDA-approved for diabetic peripheral neuropathy; one high-quality study supports use 1, 8
• Capsaicin 0.075% cream: One medium-quality study; apply to intact skin only 1, 8

Oral sodium channel blockers:

• Lamotrigine, lacosamide, carbamazepine, oxcarbazepine, valproic acid: Five medium-quality studies support use for painful diabetic peripheral neuropathy 1
• These agents are considered when first-line therapies fail or are contraindicated 1

Critical Precautions for Neuropathic Pain Treatment

• Avoid tricyclic antidepressants (which have sodium channel blocking properties) in patients ≥65 years due to anticholinergic side effects 1
• The extent to which the prohibition on sodium channel blockers in structural heart disease applies to tricyclic antidepressants remains unknown 1
• Topical agents should only be applied to intact skin to prevent excessive systemic absorption 8
• Lidocaine patches are ineffective for widespread pain distribution but may benefit nocturnal neuropathic foot pain 1

Special Populations

Patients with hyponatremia:

• Prioritize lidocaine 5% patches (up to 3 patches for 12-18 hours) for localized pain due to minimal systemic effects 7
• Consider capsaicin preparations as alternatives 7
• Avoid SNRIs which increase hyponatremia risk, especially when combined with diuretics (11.2-13.5 times increased risk) 7

Patients with renal impairment:

• Topical preparations preferred due to minimal systemic absorption 7
• If oral agents required, start with extremely low doses and titrate slowly 7

---

Key Clinical Pitfalls

• Never use Class IC agents (flecainide, propafenone) in patients with any structural heart disease, including remote MI 2, 3
• Always co-administer AV nodal blocking agents with Class IC drugs for atrial arrhythmias to prevent paradoxical ventricular rate acceleration from 1:1 atrial flutter conduction 2
• Initiate treatment in hospital for life-threatening ventricular arrhythmias 2, 3
• Monitor for proarrhythmic effects most carefully during the first week of therapy, though late events can occur 2
• Avoid capsaicin contact with eyes or mucous membranes; patients must wash hands thoroughly after application 8